Issue 1/2015
Content (80 Articles)
Sensitivity to change and prediction of global change for the Alzheimer’s Questionnaire
Michael Malek-Ahmadi, Kewei Chen, Kathryn Davis, Christine M Belden, Jessica Powell, Sandra A Jacobson, Marwan N Sabbagh
Fitting the epidemiology and neuropathology of the early stages of Alzheimer’s disease to prevent dementia
Javier Mar, Myriam Soto-Gordoa, Arantzazu Arrospide, Fermín Moreno-Izco, Pablo Martínez-Lage
Elevated cerebrovascular resistance index is associated with cognitive dysfunction in the very-old
Lindsay R Clark, Daniel A Nation, Christina E Wierenga, Katherine J Bangen, Sheena I Dev, David D Shin, Lisa Delano-Wood, Thomas T Liu, Robert A Rissman, Mark W Bondi
Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial
Manabu Ikeda, Etsuro Mori, Kazutaka Matsuo, Masaki Nakagawa, Kenji Kosaka
Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial
Etsuro Mori, Manabu Ikeda, Reiko Nagai, Kazutaka Matsuo, Masaki Nakagawa, Kenji Kosaka
Neural correlates of visual hallucinations in dementia with Lewy bodies
Camille Heitz, Vincent Noblet, Benjamin Cretin, Nathalie Philippi, Laurent Kremer, Mélanie Stackfleth, Fabrice Hubele, Jean Paul Armspach, Izzie Namer, Frédéric Blanc
The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer’s disease
Yannick Vermeiren, Debby Van Dam, Tony Aerts, Sebastiaan Engelborghs, Jean-Jacques Martin, Peter P De Deyn
Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography
Sharon J Sha, Pia M Ghosh, Suzee E Lee, Chiara Corbetta-Rastelli, Willian J Jagust, John Kornak, Katherine P Rankin, Lea T Grinberg, Harry V Vinters, Mario F Mendez, Dennis W Dickson, William W Seeley, Marilu Gorno-Tempini, Joel Kramer, Bruce L Miller, Adam L Boxer, Gil D Rabinovici
Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch
José L Molinuevo, Lutz Frölich, George T Grossberg, James E Galvin, Jeffrey L Cummings, Tillmann Krahnke, Christine Strohmaier
What we can learn from animal models about cerebral multi-morbidity
Siân Baker, Jürgen Götz
Principles and management of neuropsychiatric symptoms in Alzheimer’s dementia
Milap A Nowrangi, Constantine G Lyketsos, Paul B Rosenberg
Changes in the neurochemistry of athletes with repetitive brain trauma: preliminary results using localized correlated spectroscopy
Alexander P Lin, Saadallah Ramadan, Robert A Stern, Hayden C Box, Christopher J Nowinski, Brian D Ross, Carolyn E Mountford
A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid
Ting Yang, Tiernan T O’Malley, Daniel Kanmert, Jasna Jerecic, Lynn R Zieske, Henrik Zetterberg, Bradley T Hyman, Dominic M Walsh, Dennis J Selkoe
Linking a research register to clinical records in older adults’ mental health services: a mixed-methods study
Dan Robotham, Joanne Evans, Andrew Watson, Iain Perdue, Thomas Craig, Diana Rose, Til Wykes
Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort
Veer B Gupta, Andrea C Wilson, Samantha Burnham, Eugene Hone, Steve Pedrini, Simon M Laws, Wei Ling Florence Lim, Alan Rembach, Stephanie Rainey-Smith, David Ames, Lynne Cobiac, S Lance Macaulay, Colin L Masters, Christopher C Rowe, Ashley I Bush, Ralph N Martins
Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review
Katrin Jekel, Marinella Damian, Carina Wattmo, Lucrezia Hausner, Roger Bullock, Peter J Connelly, Bruno Dubois, Maria Eriksdotter, Michael Ewers, Elmar Graessel, Milica G Kramberger, Emma Law, Patrizia Mecocci, José L Molinuevo, Louise Nygård, Marcel GM Olde-Rikkert, Jean-Marc Orgogozo, Florence Pasquier, Karine Peres, Eric Salmon, Sietske AM Sikkes, Tomasz Sobow, René Spiegel, Magda Tsolaki, Bengt Winblad, Lutz Frölich
The relationship of weight change trajectory with medial temporal lobe atrophy in patients with mild Alzheimer’s disease: results from a cohort study
Erika Droogsma, Dieneke van Asselt, Hanneli Bieze, Nic Veeger, Peter Paul De Deyn
Alpha-synucleinopathy and neuropsychological symptoms in a population-based cohort of the elderly
Julia Zaccai, Carol Brayne, Fiona E Matthews, Paul G Ince
RETRACTED ARTICLE: Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis
Lin Tan, Lan Tan, Hui-Fu Wang, Jun Wang, Chen-Chen Tan, Meng-Shan Tan, Xiang-Fei Meng, Chong Wang, Jin-Tai Yu
Clinical and imaging features of mixed Alzheimer and vascular pathologies
Helena C Chui, Liliana Ramirez-Gomez
‘Hearts and minds’: association, causation and implication of cognitive impairment in heart failure
Jane A Cannon, John JV McMurray, Terry J Quinn
Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease
Martin R Farlow, Niels Andreasen, Marie-Emmanuelle Riviere, Igor Vostiar, Alessandra Vitaliti, Judit Sovago, Angelika Caputo, Bengt Winblad, Ana Graf
Total testosterone and neuropsychiatric symptoms in elderly men with Alzheimer’s disease
James R Hall, April R Wiechmann, Rebecca L Cunningham, Leigh A Johnson, Melissa Edwards, Robert C Barber, Meharvan Singh, Scott Winter, Sid E O’Bryant
Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer’s disease mouse model
Haakon B Nygaard, Adam C Kaufman, Tomoko Sekine-Konno, Linda L Huh, Hilary Going, Samantha J Feldman, Mikhail A Kostylev, Stephen M Strittmatter
Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants
Kristin Harkins, Pamela Sankar, Reisa Sperling, Joshua D Grill, Robert C Green, Keith A Johnson, Megan Healy, Jason Karlawish
Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimer’s disease: a voxel-based lesion mapping study
Katrin Morgen, Michael Schneider, Lutz Frölich, Heike Tost, Michael M Plichta, Heike Kölsch, Fabian Rakebrandt, Otto Rienhoff, Frank Jessen, Oliver Peters, Holger Jahn, Christian Luckhaus, Michael Hüll, Hermann-Josef Gertz, Johannes Schröder, Harald Hampel, Stefan J Teipel, Johannes Pantel, Isabella Heuser, Jens Wiltfang, Eckart Rüther, Johannes Kornhuber, Wolfgang Maier, Andreas Meyer-Lindenberg
Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis
Alireza Atri, Suzanne B Hendrix, Vojislav Pejović, Robert K Hofbauer, John Edwards, José Luis Molinuevo, Stephen M Graham
Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study
Julien Dumurgier, Susanna Schraen, Audrey Gabelle, Olivier Vercruysse, Stéphanie Bombois, Jean-Louis Laplanche, Katell Peoc’h, Bernard Sablonnière, Ksenia V Kastanenka, Constance Delaby, Florence Pasquier, Jacques Touchon, Jacques Hugon, Claire Paquet, Sylvain Lehmann
Dementia trials and dementia tribulations: methodological and analytical challenges in dementia research
Craig W Ritchie, Graciela Muniz Terrera, Terence J Quinn
Co-morbidity and systemic inflammation as drivers of cognitive decline: new experimental models adopting a broader paradigm in dementia research
Colm Cunningham, Edel Hennessy
A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease
Haakon B Nygaard, Allison F Wagner, Garrett S Bowen, Susan P Good, Martha G MacAvoy, Kurt A Strittmatter, Adam C Kaufman, Brian J Rosenberg, Tomoko Sekine-Konno, Pradeep Varma, Kewei Chen, Anthony J Koleske, Eric M Reiman, Stephen M Strittmatter, Christopher H van Dyck
Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease
Rachelle S Doody, Rema Raman, Reisa A Sperling, Eric Seimers, Gopalan Sethuraman, Richard Mohs, Martin Farlow, Takeshi Iwatsubo, Bruno Vellas, Xiaoying Sun, Karin Ernstrom, Ronald G Thomas, Paul S Aisen
HIV effects on age-associated neurocognitive dysfunction: premature cognitive aging or neurodegenerative disease?
Ronald A Cohen, Talia R Seider, Bradford Navia
Cumulative impact of health deficits, social vulnerabilities, and protective factors on cognitive dynamics in late life: a multistate modeling approach
Joshua J Armstrong, Arnold Mitnitski, Melissa K Andrew, Lenore J Launer, Lon R White, Kenneth Rockwood
Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials
Joshua D Grill, Rema Raman, Karin Ernstrom, Paul Aisen, Sherie A Dowsett, Yun-Fei Chen, Hong Liu-Seifert, Ann Marie Hake, David S Miller, Rachelle S Doody, David B Henley, Jeffrey L Cummings
Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls
Hlin Kvartsberg, Erik Portelius, Ulf Andreasson, Gunnar Brinkmalm, Konstantin Hellwig, Natalia Lelental, Johannes Kornhuber, Oskar Hansson, Lennart Minthon, Philipp Spitzer, Juan M Maler, Henrik Zetterberg, Kaj Blennow, Piotr Lewczuk
The dynamics of monocytes and microglia in Alzheimer’s disease
Peter Thériault, Ayman ElAli, Serge Rivest
Post-mortem analysis of neuroinflammatory changes in human Alzheimer’s disease
Diego Gomez-Nicola, Delphine Boche
Alzheimer’s disease progression by geographical region in a clinical trial setting
David B Henley, Sherie A Dowsett, Yun-Fei Chen, Hong Liu-Seifert, Joshua D Grill, Rachelle S Doody, Paul Aisen, Rema Raman, David S Miller, Ann M Hake, Jeffrey Cummings
Connectivity and circuitry in a dish versus in a brain
Vorapin Chinchalongporn, Peter Koppensteiner, Deborah Prè, Wipawan Thangnipon, Leonilda Bilo, Ottavio Arancio
The impact of diabetes on cognitive decline: potential vascular, metabolic, and psychosocial risk factors
Insa Feinkohl, Jackie F. Price, Mark W.J. Strachan, Brian M. Frier
Diffusion imaging changes in grey matter in Alzheimer’s disease: a potential marker of early neurodegeneration
Philip S.J. Weston, Ivor J.A. Simpson, Natalie S. Ryan, Sebastien Ourselin, Nick C. Fox
Association of cognitive function with glucose tolerance and trajectories of glucose tolerance over 12 years in the AusDiab study
Kaarin J. Anstey, Kerry Sargent-Cox, Ranmalee Eramudugolla, Dianna J. Magliano, Jonathan E. Shaw
Unraveling the potential co-contributions of cerebral small vessel vasculopathy to the pathogenesis of Alzheimer’s dementia
Jodi D. Edwards, Joel Ramirez, Sandra E. Black
A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer’s disease
Joshua D. Grill, Randall J. Bateman, Virginia Buckles, Angela Oliver, John C. Morris, Colin L. Masters, William E. Klunk, John M. Ringman
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease
Anne Rijpma, Olga Meulenbroek, Anneke M. J. van Hees, John W. C. Sijben, Bruno Vellas, Raj C. Shah, David A. Bennett, Philip Scheltens, Marcel G. M. Olde Rikkert
Report from the Alzheimer’s Research UK Conference 2015
Rosa M. Sancho, Carla J. Cox, Simon H. Ridley, Laura E. Phipps, Eric Karran
An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter
Brendan P. Lucey, Celedon Gonzales, Ujjwas Das, Jinhe Li, Eric R. Siemers, J. Randall Slemmon, Randall J. Bateman, Yafei Huang, Gerard B. Fox, Jurgen A.H.R. Claassen, Diane Slats, Marcel M. Verbeek, Gary Tong, Holly Soares, Mary J. Savage, Matthew Kennedy, Mark Forman, Magnus Sjögren, Richard Margolin, Xia Chen, Martin R. Farlow, Robert A. Dean, Jeffrey F. Waring
Modulation of Aβ42 in vivo by γ-secretase modulator in primates and humans
I-Fang Ling, Todd E. Golde, Douglas R. Galasko, Edward H. Koo
Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains
Douglas G. Walker, Lih-Fen Lue
Re-examining tau-immunoreactive pathology in the population: granulovacuolar degeneration and neurofibrillary tangles
Sally Hunter, Thais Minett, Tuomo Polvikoski, Elizabeta Mukaetova-Ladinska, Carol Brayne
Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects
Artur M N Coutinho, Fábio H G Porto, Fabio L S Duran, Silvana Prando, Carla R Ono, Esther A A F Feitosa, Lívia Spíndola, Maira O. de Oliveira, Patrícia H F do Vale, Helio R. Gomes, Ricardo Nitrini, Sonia M D Brucki, Carlos A. Buchpiguel
Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort
Maartje I. Kester, Charlotte E. Teunissen, Courtney Sutphen, Elizabeth M. Herries, Jack H. Ladenson, Chengjie Xiong, Philip Scheltens, Wiesje M. van der Flier, John C. Morris, David M. Holtzman, Anne M. Fagan
The Third French Alzheimer Plan: analysis of the influence of a national public health initiative on scientific research productivity and impact
Nicole Haeffner-Cavaillon, Patrick Devos, Sylvie Ledoux, Joël Ménard
Verbal and non-verbal memory and hippocampal volumes in a memory clinic population
Aaron Bonner-Jackson, Shamseldeen Mahmoud, Justin Miller, Sarah J Banks
Assessing clinicopathological correlation in chronic traumatic encephalopathy: rationale and methods for the UNITE study
Jesse Mez, Todd M. Solomon, Daniel H. Daneshvar, Lauren Murphy, Patrick T. Kiernan, Philip H. Montenigro, Joshua Kriegel, Bobak Abdolmohammadi, Brian Fry, Katharine J. Babcock, Jason W. Adams, Alexandra P. Bourlas, Zachary Papadopoulos, Lisa McHale, Brent M. Ardaugh, Brett R. Martin, Diane Dixon, Christopher J. Nowinski, Christine Chaisson, Victor E. Alvarez, Yorghos Tripodis, Thor D. Stein, Lee E. Goldstein, Douglas I. Katz, Neil W. Kowall, Robert C. Cantu, Robert A. Stern, Ann C. McKee
Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients
Malin Wennström, Sara Hall, Katarina Nägga, Elisabet Londos, Lennart Minthon, Oskar Hansson
New scoring methodology improves the sensitivity of the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials
Nishant Verma, S. Natasha Beretvas, Belen Pascual, Joseph C. Masdeu, Mia K. Markey
Association between dental amalgam fillings and Alzheimer’s disease: a population-based cross-sectional study in Taiwan
Yi-Hua Sun, Oswald Ndi Nfor, Jing-Yang Huang, Yung-Po Liaw
Compression or expansion of dementia in Germany? An observational study of short-term trends in incidence and death rates of dementia between 2006/07 and 2009/10 based on German health insurance data
Gabriele Doblhammer, Anne Fink, Stephanie Zylla, Frans Willekens
The need for thorough phase II studies in medicines development for Alzheimer’s disease
Julian A. Gray, David Fleet, Bengt Winblad
Predicting Alzheimer's disease development: a comparison of cognitive criteria and associated neuroimaging biomarkers
Brandy L. Callahan, Joel Ramirez, Courtney Berezuk, Simon Duchesne, Sandra E. Black
Improved predictive ability of the Montreal Cognitive Assessment for diagnosing dementia in a community-based study
Jung-Lung Hsu, Yen-Chun Fan, Ya-Li Huang, Jui Wang, Wei-Hung Chen, Hou-Chang Chiu, Chyi-Huey Bai
Central delivery of iodine-125–labeled cetuximab, etanercept and anakinra after perispinal injection in rats: possible implications for treating Alzheimer’s disease
Megan E. Roerink, Rob JM Groen, Gerben Franssen, Bianca Lemmers-van de Weem, Otto C. Boerman, Jos WM van der Meer
Alzheimer’s disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology
Alan Rembach, Lisbeth A. Evered, Qiao-Xin Li, Tabitha Nash, Lesley Vidaurre, Christopher J. Fowler, Kelly K. Pertile, Rebecca L. Rumble, Brett O. Trounson, Sarah Maher, Francis Mooney, Maree Farrow, Kevin Taddei, Stephanie Rainey-Smith, Simon M. Laws, S. Lance Macaulay, William Wilson, David G. Darby, Ralph N. Martins, David Ames, Steven Collins, Brendan Silbert, Colin L. Masters, James D. Doecke
Hippocampal atrophy but not white-matter changes predicts the long-term cognitive response to cholinesterase inhibitors in Alzheimer’s disease
Yu-Wen Cheng, Ta-Fu Chen, Ting-Wen Cheng, Ya-Mei Lai, Mau-Sun Hua, Ya-Fang Chen, Ming-Jang Chiu
Role of ABCA7 loss-of-function variant in Alzheimer's disease: a replication study in European–Americans
Jorge L. Del-Aguila, Maria Victoria Fernández, Jessica Jimenez, Kathleen Black, Shengmei Ma, Yuetiva Deming, David Carrell, Ben Saef, Bill Howells, John Budde, Carlos Cruchaga
Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease
Konstantin Hellwig, Hlin Kvartsberg, Erik Portelius, Ulf Andreasson, Timo Jan Oberstein, Piotr Lewczuk, Kaj Blennow, Johannes Kornhuber, Juan Manuel Maler, Henrik Zetterberg, Philipp Spitzer
Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease
Katarzyna Adamczuk, Jolien Schaeverbeke, Hugo M. J. Vanderstichele, Johan Lilja, Natalie Nelissen, Koen Van Laere, Patrick Dupont, Kelly Hilven, Koen Poesen, Rik Vandenberghe
In vivo molecular neuroimaging of glucose utilization and its association with fibrillar amyloid-β load in aged APPPS1-21 mice
Ann-Marie Waldron, Cindy Wintmolders, Astrid Bottelbergs, Jonathan B. Kelley, Mark E. Schmidt, Sigrid Stroobants, Xavier Langlois, Steven Staelens
APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment
Simon Sjödin, Kerstin K. A. Andersson, Marc Mercken, Henrik Zetterberg, Herman Borghys, Kaj Blennow, Erik Portelius
Microstate connectivity alterations in patients with early Alzheimer’s disease
Florian Hatz, Martin Hardmeier, Nina Benz, Michael Ehrensperger, Ute Gschwandtner, Stephan Rüegg, Christian Schindler, Andreas U. Monsch, Peter Fuhr
Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software
Sanjida Akter, Md. Rajib Hassan, Mohammad Shahriar, Nahia Akter, Md. Golam Abbas, Mohiuddin Ahmed Bhuiyan